Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Given Average Rating of “Moderate Buy” by Brokerages

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) has received an average recommendation of “Moderate Buy” from the ten brokerages that are currently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation and nine have issued a buy recommendation on the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $41.7778.

TEVA has been the subject of several research reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research note on Monday, April 20th. JPMorgan Chase & Co. raised their target price on shares of Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company an “overweight” rating in a research note on Thursday, April 30th. Barclays lifted their target price on shares of Teva Pharmaceutical Industries from $38.00 to $40.00 and gave the company an “overweight” rating in a report on Wednesday, May 6th. Piper Sandler reaffirmed an “overweight” rating and set a $42.00 price target (up from $41.00) on shares of Teva Pharmaceutical Industries in a research report on Thursday, April 30th. Finally, UBS Group increased their price target on Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the company a “buy” rating in a report on Thursday, April 30th.

Teva Pharmaceutical Industries Stock Performance

NYSE TEVA opened at $32.24 on Friday. The firm has a market capitalization of $37.07 billion, a P/E ratio of 24.24, a P/E/G ratio of 3.33 and a beta of 0.86. Teva Pharmaceutical Industries has a 1-year low of $14.99 and a 1-year high of $37.35. The company has a debt-to-equity ratio of 1.70, a current ratio of 1.01 and a quick ratio of 0.78. The business’s 50-day simple moving average is $33.83 and its 200-day simple moving average is $32.70.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its earnings results on Tuesday, March 31st. The company reported $0.53 earnings per share (EPS) for the quarter. The firm had revenue of $3.98 billion during the quarter. Teva Pharmaceutical Industries had a net margin of 9.01% and a return on equity of 43.53%. Equities analysts predict that Teva Pharmaceutical Industries will post 1.99 EPS for the current year.

Insider Activity at Teva Pharmaceutical Industries

In related news, CAO Amir Weiss sold 10,679 shares of the firm’s stock in a transaction dated Wednesday, May 6th. The stock was sold at an average price of $36.00, for a total transaction of $384,444.00. Following the sale, the chief accounting officer directly owned 20,016 shares in the company, valued at approximately $720,576. This trade represents a 34.79% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Richard Daniell sold 30,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 5th. The stock was sold at an average price of $35.40, for a total value of $1,062,000.00. Following the transaction, the executive vice president directly owned 55,755 shares in the company, valued at $1,973,727. This trade represents a 34.98% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 465,931 shares of company stock valued at $16,332,989 over the last 90 days. Corporate insiders own 0.54% of the company’s stock.

Institutional Trading of Teva Pharmaceutical Industries

Large investors have recently bought and sold shares of the company. Aster Capital Management DIFC Ltd purchased a new stake in shares of Teva Pharmaceutical Industries during the fourth quarter valued at approximately $25,000. Cornerstone Planning Group LLC grew its holdings in Teva Pharmaceutical Industries by 547.1% during the 1st quarter. Cornerstone Planning Group LLC now owns 893 shares of the company’s stock valued at $27,000 after purchasing an additional 755 shares in the last quarter. Allworth Financial LP grew its holdings in Teva Pharmaceutical Industries by 53.8% during the 4th quarter. Allworth Financial LP now owns 941 shares of the company’s stock valued at $29,000 after purchasing an additional 329 shares in the last quarter. Grove Bank & Trust increased its stake in Teva Pharmaceutical Industries by 300.0% during the 4th quarter. Grove Bank & Trust now owns 1,000 shares of the company’s stock worth $31,000 after buying an additional 750 shares during the period. Finally, EverSource Wealth Advisors LLC increased its stake in Teva Pharmaceutical Industries by 51.8% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,011 shares of the company’s stock worth $32,000 after buying an additional 345 shares during the period. Institutional investors and hedge funds own 54.05% of the company’s stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.